William Blair Begins Coverage on Kyverna Therapeutics (NASDAQ:KYTX)

Key Points

• William Blair has initiated coverage of Kyverna Therapeutics (NASDAQ:KYTX) with an "outperform" rating, while HC Wainwright upgraded the stock from "neutral" to "buy" and raised its price target from $4.00 to $5.00.
• Kyverna Therapeutics has a current stock price of $3.30, with a market cap of approximately $142.71 million, and its consensus price target stands at $15.60.
• The company reported an earnings per share (EPS) of ($0.97) for the last quarter, exceeding the consensus estimate by $0.03, while institutional investors currently hold 18.08% of its shares.

Stock analysts at William Blair initiated coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an "outperform" rating on the stock. William Blair also issued estimates for Kyverna Therapeutics' Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($4.21) EPS and FY2027 earnings at ($3.54) EPS.

Separately, HC Wainwright upgraded shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $4.00 to $5.00 in a research report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $15.60.

Kyverna Therapeutics Stock Performance

Shares of KYTX stock traded down $0.06 during mid-day trading on Wednesday, hitting $3.79. 103,264 shares of the stock were exchanged, compared to its average volume of 370,238. The stock's fifty day simple moving average is $3.46 and its two-hundred day simple moving average is $2.80. The stock has a market capitalization of $163.92 million, a price-to-earnings ratio of -1.03 and a beta of 3.05. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $8.70.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.03. On average, research analysts expect that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of Kyverna Therapeutics by 21.7% in the fourth quarter. Geode Capital Management LLC now owns 539,682 shares of the company's stock valued at $2,019,000 after acquiring an additional 96,370 shares during the period. Wells Fargo & Company MN raised its stake in Kyverna Therapeutics by 16.4% in the fourth quarter. Wells Fargo & Company MN now owns 179,012 shares of the company's stock valued at $670,000 after purchasing an additional 25,225 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Kyverna Therapeutics in the fourth quarter valued at approximately $167,000. Barclays PLC raised its stake in shares of Kyverna Therapeutics by 27.7% during the fourth quarter. Barclays PLC now owns 89,586 shares of the company's stock worth $336,000 after acquiring an additional 19,419 shares in the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Kyverna Therapeutics during the fourth quarter worth approximately $147,000. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.